What's hot amongst the up and coming CAR-T cell therapies in early development?
Will 2024 be a 'Zeitenwende' moment for the IO field..
Small molecule and ADC standouts – a guest post
Which Thunderbirds are Go in this niche?!
Things seen in the mirror may be nearer than you think
Going beyond gene edited CARs
A smorgasbord of bispecifics and CAR-T cells for autoimmune diseases
Reflections on how to overcome hurdles associated with CAR-T cell resistance
Are there hideen treasures in Yokohama, Japan
A look atfive recent developments and what we can learn from them
Early stage oncology new product development is a rather strange beast at times. On the one hand is the…
How pivoting therapy areas might make a real impact for several refractory diseases
When CAR-T and bispecifics create a crowded competitive landscape
What's looking interesting in early stage trials at ASCO24?
Will new developments in tackling cytokines fare better in the clinic than the first generation attempts?
Sometimes oncology new product development can be fascinating to watch from the sidelines. There are…
A look at an emerging early stage product which is looking intriguing
Winners and losers at JPM24
Next generation CAR-T cells are coming to the clinic in 2024
Improving T cell fitness is an important goal for researchers in 2024
It's beginning to look a lot like Christmas...
The Yin and Yang of NK and T cells and how this can impact therapies
What to watch for in emerging CAR-T cell therapy approaches and how they may give antibodies a run for their money
10 IO topics to watch out for at ASH23
How a competitive landscape can change drastically over a short time
Pulling disparate sources together to develop a more optimised approach to targeting oncoproteins
A look at the potential missing piece in making bispecifics even better
W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
Will in vivo CAR-T cell therapies go prime time?
Eight key areas to watch out for at SITC 2023!
Dawn of a new IO era at ESMO23?
Important new findings on the cell therapy front
There's a huge surge in ADCs in the clinic but how many will make an impact?
From CAR-T cells to protein degradation
Early-stage agents in development for multiple myeloma - hit or miss?
Challenges and opportunities in the myeloma niche
Some perspectives on the balancing act required between stimulus and response
Progress report on a varied China based CAR-T cell program
When an established concept is finally coming of age with new colours...
Taking a different approach to CAR design with some positive data to show for it
Encouraging new developments in the CAR-NK niche
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
Next generation CAR-T cell therapies for solid tumours
What's new on the CAR-T cell therapy front?
The ever evolving selective KRAS inhibitor & degrader space
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
Early stage new product development part 1 - seeing the wood from the trees
Half a dozen key early areas to watch out for
In a few years time the next generation CAR-T cell therapies are going to look and behave very…
Improving cell therapy performance with a multitude of innovative strategies
Key developments which could kickstart a renaissance for CAR-T cells in solid tumours
A look at some new developments in CAR-T cell therapy for gliomas
We have heard much over the last decade or so about the impact of the microbiome on responses to…
The next generation of CAR-T cell therapy will require out of the box thinking
How base editing can transform the development of next gen CAR-T cell therapies
Some promising new early developments are coming through in AML and T-ALL - what's the skinny?
A rising area of interest in the CAR-T cell space
What will be the emerging products and regimens to watch out for in aggressive lymphomas?
How can performance of T cell therapy be improved?
The evolving BMS-Celgene pipeline and what's coming next in new developmental twists
Ten emerging development areas to watch out for in oncology during 2023
The importance of T cell exhaustion and exploring ways to avoid it
10 early stage IO biotechs to watch out for
Half a dozen key posters to watch out for in early stage oncology at SITC22
6 abstracts to watch out for on how to overcome immune escape
Bispecifics come and bispecifics go as companies seek to find a balance
In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…
Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.
First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22
The continuous evolution of BCMA CAR-T cell therapy products and how they are doing
A look at early stage CAR-T cell therapies in development
What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?
5 abstracts to watch out for at the ASCO22 meeting in Chicago
New CAR-T cell developments in solid tumours - hit or miss?
Looking beyond the hype from a broader perspective
5 key and novel early areas of development which stood out to us at AACR22
CAR-T cells have struggled to make an impact in solid tumours, are things changing for the better?
A look at new and quite unexpected directions for CAR-T cell therapy
Highlights from Day 1 of CART22, part 1
Some important new papers on CAR-T cell therapies are shedding light on potential new combination strategies
A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study
Part 2 of our mini-series on Next Generation CAR-T cells
Overcoming the limitations associated with CAR-T performance and lack of persistence
Several controversies abound in the CAR-T cell niche this year, plus what's coming next?
Finessing oncology targets can be both tricky and challenging. Does changing the modality help?
Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic
SITC 2021 Preview
Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies
A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.
13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?
Noteworthy AACR21 on-demand presentations.
Exploring a novel approach to overcoming immunotherapy resistance
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy
Commentary on Saturday at ASH20
Rock around the CAR-T cell clock to learn what to watch out for at ASH20!
Science drives oncology new product development and the AACR special conferences are always a good place…
How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development
Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies
Using CRISPR screens to find new targets for enhancing T cell fitness
How can we use metabolic reprogramming to enhance CAR T cell therapy?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?
Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20
In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session
Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20
Ten intriguing novel agents in early development to watch out for
How can we go about improving cell therapy approaches?
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering
Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain
Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting
Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain
Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?
Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them
There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.
Is T cell therapy like Game of Thrones?
Can gamma delta T cells be effective as a therapeutic in GBM?
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
A snapshot of 3 UK cell therapy companies, Autolus, Achilles and GammaDelta Therapeutics
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
What can we learn about gamma delta T cell cancer immunotherapy in China?
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?
Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
An extensive round-up of what to expect from SITC18 ahead of the abstract reveal
Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens
Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18
Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies
Update on BCMA, SLAMF7 and other targets in multiple myeloma
Lessons learned from recent failure and a look at where a few new developments might be coming from...
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
On launched products, armored CARs and the potential threat from China
An in-depth look at Adaptimmune's TCR T cell therapy program
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at the history of NK cell development and where we're going in future with this IO approach
Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area
A look at an emerging area for biomarkers and stealth cancer therapeutics
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space
What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?
A look at Dr Malcolm Brenner's work on virus specific T cell therapies
FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment
A look at what's hot in CAR T cell therapies at #ASH17
A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).
Some intriguing surprises in the CAR T cell therapy abstracts this year...
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
Encouraging new developments in GBM with a novel CAR T cell therapy
After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH
A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma
A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16
What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
A primer on neoantigens and their importance in cancer research
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.
What does the evolving landscape for CAR, TIL and TCR cell therapies look like?
The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.
Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
